We have located links that may give you full text access.
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil.
OBJECTIVE: To investigate the effect of simultaneous and delayed administration of activated charcoal on the absorption of two verapamil formulations.
METHODS: In the first study, 9 healthy volunteers received the following treatments: 1) verapamil 80 mg (conventional formulation) with 50 mL water only, 2) verapamil 80 mg and 25 g activated charcoal immediately afterwards, and 3) verapamil 80 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion. In the second study, 8 healthy volunteers received the following treatments: 1) verapamil 240 mg (slow-release formulation) with 50 mL water only, 2) verapamil slow-release 240 mg and 25 g activated charcoal immediately afterwards, 3) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion, and 4) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 4 h later. Plasma verapamil concentrations over 24 h were measured by high performance liquid chromatography.
RESULTS: Activated charcoal given immediately after the conventional formulation of verapamil reduced the AUC0-24 h by 99% (p < 0.0005) and the Cmax by 98% (p < 0.0005). When the administration of charcoal was delayed 2 h, no significant change in verapamil absorption was observed. With the slow-release formulation of verapamil, charcoal given immediately after verapamil ingestion reduced the verapamil AUC0-24 h by 86% (p = 0.001) and the Cmax by 82% (p = 0.002). When the administration of charcoal was delayed 2 or 4 h, the AUC0-24 h was reduced by 35% (p = 0.04) and 32% (p = 0.001), respectively, but the Cmax was decreased by 13% (p = NS) and 9% (p = NS) only.
CONCLUSIONS: Activated charcoal was effective in preventing absorption of verapamil when it was administered immediately after verapamil ingestion. In the case of slow-release formulation, charcoal reduced verapamil absorption by over 30% even when given 4 h after verapamil.
METHODS: In the first study, 9 healthy volunteers received the following treatments: 1) verapamil 80 mg (conventional formulation) with 50 mL water only, 2) verapamil 80 mg and 25 g activated charcoal immediately afterwards, and 3) verapamil 80 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion. In the second study, 8 healthy volunteers received the following treatments: 1) verapamil 240 mg (slow-release formulation) with 50 mL water only, 2) verapamil slow-release 240 mg and 25 g activated charcoal immediately afterwards, 3) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion, and 4) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 4 h later. Plasma verapamil concentrations over 24 h were measured by high performance liquid chromatography.
RESULTS: Activated charcoal given immediately after the conventional formulation of verapamil reduced the AUC0-24 h by 99% (p < 0.0005) and the Cmax by 98% (p < 0.0005). When the administration of charcoal was delayed 2 h, no significant change in verapamil absorption was observed. With the slow-release formulation of verapamil, charcoal given immediately after verapamil ingestion reduced the verapamil AUC0-24 h by 86% (p = 0.001) and the Cmax by 82% (p = 0.002). When the administration of charcoal was delayed 2 or 4 h, the AUC0-24 h was reduced by 35% (p = 0.04) and 32% (p = 0.001), respectively, but the Cmax was decreased by 13% (p = NS) and 9% (p = NS) only.
CONCLUSIONS: Activated charcoal was effective in preventing absorption of verapamil when it was administered immediately after verapamil ingestion. In the case of slow-release formulation, charcoal reduced verapamil absorption by over 30% even when given 4 h after verapamil.
Full text links
Related Resources
Trending Papers
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives.Cardiovascular Diabetology 2024 November 15
Methods for determining optimal positive end-expiratory pressure in patients undergoing invasive mechanical ventilation: a scoping review.Canadian Journal of Anaesthesia 2024 November 20
Cardiac Failure and Cardiogenic Shock: Insights Into Pathophysiology, Classification, and Hemodynamic Assessment.Curēus 2024 October
The Management of Interstitial Lung Disease in the ICU: A Comprehensive Review.Journal of Clinical Medicine 2024 November 6
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app